Placebo-controlled double-blind dose-response study of the non-purine-selective xanthine oxidase inhibitor febuxostat (TMX-67) in patients with hyperuricemia (including gout patients) in japan: late phase 2 clinical study.

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases

Volumn 17, Issue 4 Suppl 2, 2011, Pages

  Naoyuki, Kamatani ^a   Shin, Fujimori ^b   Toshikazu, Hada ^b   Tatsuo, Hosoya ^b   Kenjiro, Kohri ^b   Toshitaka, Nakamura ^b   Takanori, Ueda ^b   Tetsuya, Yamamoto ^b   Hisashi, Yamanaka ^b   Yuji, Matsuzawa ^b  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGOUT AGENT; FEBUXOSTAT; THIAZOLE DERIVATIVE; URIC ACID; XANTHINE OXIDASE;

ARTICLE; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ANTAGONISM; FEMALE; FOLLOW UP; GOUT; HUMAN; HYPERURICEMIA; JAPAN; MALE; MIDDLE AGED; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; GOUT; GOUT SUPPRESSANTS; HUMANS; HYPERURICEMIA; JAPAN; MALE; MIDDLE AGED; THIAZOLES; TREATMENT OUTCOME; URIC ACID; XANTHINE OXIDASE;

EID: 84863972656     PISSN: None     EISSN: 15367355     Source Type: Journal    
DOI: None     Document Type: Article

References (0)